Last reviewed · How we verify
NCT05288179
Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis
Phase 3 trial testing Pirfenidone Capsules in Pneumoconiosis in 272 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | Beijing Continent Pharmaceutical Co, Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 272 |
| Start date | 7 June 2022 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Pirfenidone Capsules — full drug profile →
- placebo capsules — full drug profile →
Conditions studied
- Pneumoconiosis — all drugs for Pneumoconiosis →
Sponsor
Beijing Continent Pharmaceutical Co, Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Pneumoconiosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a randomized, double-blind, placebo-controlled, multicenter clinical study. The main purpose of this study was to confirm the efficacy and safety of pirfenidone capsules in the treatment of pneumoconiosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review.
Amati F, Stainer A, Polelli V, Mantero M, et al · · 2023 · cited 45× · PMID 37175556 · DOI 10.3390/ijms24097849
Verify or expand the search:
- PubMed search for NCT05288179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pirfenidone Capsules
Trials testing the same drug.
- NCT07325357 — Effect of Pirfenidone on TA Fibrosis · Phase 4 · not yet recruiting
Other recruiting trials for Pneumoconiosis
Currently open trials in the same condition.
- NCT07077382 — Pneumoconiosis and Dust Exposure China Cohort · recruiting
Other Beijing Continent Pharmaceutical Co, Ltd. trials
Trials by the same sponsor.
- NCT07471217 — [¹⁴C] Hydronidone Mass Balance Study · Phase 1 · not yet recruiting
- NCT07343778 — A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis · Phase 3 · recruiting
- NCT07417553 — A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis · Phase 2 · not yet recruiting
- NCT07364448 — A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis · Phase 2 · recruiting
- NCT07388680 — Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia · Phase 2, PHASE3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05288179 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Continent Pharmaceutical Co, Ltd.
- Last refreshed: 24 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05288179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing